Aviragen Therapeutics (AVIR) Misses Q1 EPS by 1c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56).

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Anthropic Expected to Tell Investors It Sees a More Than $30T Total Addressable Market - WSJ
• Urban Outfitters (URBN) call put ratio 1 call to 1.2 puts into quarter results
• Abercrombie & Fitch (ANF) call put ratio 1 call to 1.4 puts into quarter results